U

United Laboratories International Holdings Ltd
HKEX:3933

Watchlist Manager
United Laboratories International Holdings Ltd
HKEX:3933
Watchlist
Price: 12.34 HKD 5.11% Market Closed
Market Cap: 22.4B HKD
Have any thoughts about
United Laboratories International Holdings Ltd?
Write Note

United Laboratories International Holdings Ltd
Retained Earnings

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

United Laboratories International Holdings Ltd
Retained Earnings Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Retained Earnings CAGR 3Y CAGR 5Y CAGR 10Y
U
United Laboratories International Holdings Ltd
HKEX:3933
Retained Earnings
ÂĄ13.5B
CAGR 3-Years
37%
CAGR 5-Years
29%
CAGR 10-Years
17%
G
Grand Pharmaceutical Group Ltd
HKEX:512
Retained Earnings
HK$15.7B
CAGR 3-Years
43%
CAGR 5-Years
45%
CAGR 10-Years
39%
Sino Biopharmaceutical Ltd
HKEX:1177
Retained Earnings
ÂĄ22.5B
CAGR 3-Years
24%
CAGR 5-Years
6%
CAGR 10-Years
22%
C
China Traditional Chinese Medicine Holdings Co Ltd
HKEX:570
Retained Earnings
ÂĄ9.6B
CAGR 3-Years
10%
CAGR 5-Years
17%
CAGR 10-Years
37%
C
China Resources Pharmaceutical Group Ltd
HKEX:3320
Retained Earnings
HK$25.7B
CAGR 3-Years
9%
CAGR 5-Years
11%
CAGR 10-Years
N/A
H
HUTCHMED (China) Ltd
HKEX:13
Retained Earnings
-$845.1m
CAGR 3-Years
-18%
CAGR 5-Years
-30%
CAGR 10-Years
-29%
No Stocks Found

United Laboratories International Holdings Ltd
Glance View

Market Cap
22.4B HKD
Industry
Pharmaceuticals

United Laboratories International Holdings Ltd. has carved a significant niche in the global pharmaceutical industry, primarily through its prowess in producing antibiotic finished products and intermediates. Headquartered in Hong Kong, the company operates a diversified business model that spans manufacturing, marketing, and distribution of a wide range of pharmaceutical products. United Laboratories has established robust production facilities in China, positioning itself as one of the leading producers of antibiotics like amoxicillin and ampicillin. These products are vital to combating infections and are critical components in healthcare systems worldwide. The company's vertically integrated operations, coupled with its strategic focus on research and development, enable it to maintain cost efficiency while innovating continuously within its drug portfolio. The company's revenue mechanism is firmly rooted in its extensive distribution network and expansive market reach, which traverse not only the domestic markets but also international territories in North America, Europe, and Asia. United Laboratories leverages its strong brand presence and economies of scale to offer competitive pricing, enhancing its market penetration. Furthermore, it capitalizes on favorable regulatory frameworks in emerging markets, creating a tapestry of growth opportunities. The company's business strategy is also marked by its commitment to quality and adherence to stringent production standards, essential for maintaining trust and reliability among healthcare providers. Through these strategic channels, United Laboratories International Holdings Ltd. sustains its growth and profitability in the dynamic pharmaceutical landscape.

Intrinsic Value
21.1 HKD
Undervaluation 42%
Intrinsic Value
Price
U

See Also

What is United Laboratories International Holdings Ltd's Retained Earnings?
Retained Earnings
13.5B CNY

Based on the financial report for Jun 30, 2024, United Laboratories International Holdings Ltd's Retained Earnings amounts to 13.5B CNY.

What is United Laboratories International Holdings Ltd's Retained Earnings growth rate?
Retained Earnings CAGR 10Y
17%

Over the last year, the Retained Earnings growth was 17%. The average annual Retained Earnings growth rates for United Laboratories International Holdings Ltd have been 37% over the past three years , 29% over the past five years , and 17% over the past ten years .

Back to Top